



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

5 Jul 2021 (#20)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

[NOT-HD-21-038](#) Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities. Vaccines are a central component of preventive care for populations of high priority to the NICHD. NICHD's priority populations include infants, children, adolescents, pregnant and lactating women, and persons with physical and intellectual disabilities, particularly those who are also underserved or experience health disparities. Strategies that promote access, acceptance and uptake of CDC-recommended vaccines among these populations have the potential not only to reduce the incidence of vaccine-preventable diseases, but also to promote health and well-being and to improve trust in science and health care. This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through September 8, 2024. Submit applications for this initiative using one of the following funding opportunity announcements

- [PA-20-200](#) - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-21-221](#) - NICHD Small Research Grant Program (R03 Clinical Trial Required)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

[NOT-OD-21-092](#) Notice of Special Interest (NOSI): Use of Digital Technology and Mobile Health (mHealth) to Improve Diagnosis, Assessments, Interventions, Management and Outcomes for Individuals with Down Syndrome (DS) Across the Lifespan (R21 Clinical Trial Not Allowed). This Notice invites applications specifically aimed at developing or building upon existing technological tools to improve diagnosis, assessments, interventions, management, and outcomes for infants, children, adolescents and adults with DS. Applications in response to this NOSI should be aligned with the INCLUDE Project [Research Plan](#). Submit applications for this initiative using the following funding opportunity announcement (FOA) [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed).

[NOT-OD-21-127](#) Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects. The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive. This notice applies to due dates on or after June 5, 2019 and subsequent receipt dates through September 8, 2022. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs)

- [PA-19-055](#) - NIH Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-19-056](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-19-091](#) - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

[NOT-OD-21-137](#) Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Population, Clinical and Applied Prevention Mechanisms of Health Effects.

Research with a focus on other non-combustible nicotine and tobacco products will be considered on a case-by-case basis. Studies should examine population-based, clinical, and applied prevention of disease, including etiology and epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive. This notice applies to due dates on or after June 5, 2019 and subsequent receipt dates through September 8, 2022. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs)

- [PA-19-055](#) - NIH Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-19-056](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-19-091](#) – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. National Eye Institute ([NEI](#)) Vision Research Epidemiology Grant (UG1 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-204](#)

Type: UG1

Application Due Date: September 25, 2021, September 25, 2021, May 25, 2022. Aids dates: January 07, 2022; May 07, 2022; September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is five years.

2. Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-029](#)

Type: R61/R33

Application Due Date: October 14, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship between sleep and substance use disorders (SUDs). Projects may explore the molecular, cellular, circuit and behavioral interactions between sleep and SUDs.

Budget: NIDA intends to commit \$ 3.5M in FY 2022 to fund 2-5 awards across this and the companion FOAs. Application direct costs are limited to \$250,000 during each year of the R61 phase and \$500,000 during each year of the R33 phase. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. The scope of the proposed project should determine the requested project period.

3. Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DE-22-003](#)

Type: R01

Application Due Date: November 18, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit research to better understand the epidemiology and biology of oral human papillomavirus (HPV) infection, its acquisition and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV. The FOA intends to address broad knowledge gaps related to biological, immunogenetic, clinical, and socio-behavioral factors and mechanisms for oral HPV co-infection and persistence in the oral cavity and oropharynx of HIV-seropositive individuals.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DE-22-004](#)

Type: R21

Application Due Date: November 18, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit research to better understand the epidemiology and biology of oral human papillomavirus (HPV) infection, its acquisition and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV. The FOA intends to address broad knowledge gaps related to biological, immunogenetic, clinical, and socio-behavioral factors and mechanisms for oral HPV co-infection and persistence in the oral cavity and oropharynx of HIV-seropositive individuals.

Budget: The maximum project period is 2 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105